Therapy Detail

Therapy Name Ramucirumab
Therapy Description

Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (NCI Drug Dictionary). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ramucirumab Cyramza LY3009806 VEGFR2 Antibody 4 Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (NCI Drug Dictionary). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastroesophageal junction adenocarcinoma not applicable Ramucirumab FDA approved Actionable In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) increased progression-free and overall survival in patients with gastroesophageal junction adenocarcinoma (PMID: 24094768). detail... 24094768
Unknown unknown ovary epithelial cancer not applicable Ramucirumab Phase II Actionable In a Phase II trial, Cyramza (ramucirumab) resulted in antitumor activity in patients with epithelial ovarian cancer (PMID: 25016924). 25016924
Unknown unknown hepatocellular carcinoma conflicting Ramucirumab Phase III Actionable In a Phase III trial (REACH), treatment with Cyramza (ramucirumab) did not result in improved overall survival (OS) compared to placebo (9.2 vs. 7.6 months; HR 0.87 [95% CI 0.72-1.05]; p=0.14) in patients with hepatocellular carcinoma (PMID: 26095784). However, potential benefit on OS (HR 0.80, p=0.06) was observed in patients with a Child-Pugh score of 5 (PMID: 27657674; NCT01140347). 26095784 27657674
Unknown unknown hepatocellular carcinoma conflicting Ramucirumab Phase III Actionable In a Phase III trial (REACH-2), Cyramza (ramucirumab) treatment resulted in significantly improved overall survival (8.7 vs 7.3 months, HR=0.71, p=0.0199) and progression-free survival (2.8 vs 1.6 months, HR=0.452, p<0.0001) in hepatocellular carcinoma patients with baseline AFP ?400 ng/ml, and progressed on or were intolerant to Nexavar (sorafenib) (J Clin Oncol 36, 2018 (suppl; abstr 4003); NCT02435433). detail...
Unknown unknown papillary thyroid carcinoma not applicable Ramucirumab Phase I Actionable In a Phase I trial, Cyramza (ramucirumab) demonstrated safety and efficacy resulting in partial response or stable disease in patients with advanced solid tumors, including papillary thyroid carcinoma (PMID: 20048182). 20048182
Unknown unknown biliary tract cancer not applicable Ramucirumab Phase II Actionable In a Phase II trial, Cyramza (ramucirumab) treatment resulted in a progression-free survival of 2.73 months, an overall survival of 6.31 months, 0% objective response rate, and a disease control rate of 44% (15/34) in patients with advanced biliary cancer(J Clin Oncol 36, 2018 (suppl; abstr 4081); NCT02520141). detail...
Unknown unknown melanoma not applicable Ramucirumab Phase II Actionable In a Phase II trial, Cyramza (ramucirumab), with or without Deticene (dacarbazine), demonstrated safety and efficacy in patients with metastatic melanoma. The combined therapy appeared to be associated with improved progression free survival relative to monotherapy (J Clin Oncol 28:15s, 2010 (suppl; abstr 8519)). detail...
KDR wild-type Advanced Solid Tumor predicted - sensitive Ramucirumab Phase I Actionable In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182). 20048182
Unknown unknown stomach cancer not applicable Ramucirumab FDA approved Actionable In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) increased progression-free and overall survival in patients with advanced gastric cancer (PMID: 24094768). 24094768 detail...
Unknown unknown duodenum adenocarcinoma not applicable Ramucirumab Phase II Actionable In a Phase II study, Cyramza (ramuciramab), in combination with mFOLFOX-6 chemotherapy regimen (Wellcovorin (leucovorin), Adrucil (fluorouracil) and Eloxatin (oxaliplatin)), demonstrated safety and efficacy in metastatic colorectal cancer (PMID: 24674871). 24674871
Clinical Trial Phase Therapies Title Recruitment Status
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Active, not recruiting
NCT02443883 Phase II Ramucirumab A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Active, not recruiting
NCT02564198 Phase I Ramucirumab A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Recruiting
NCT02514551 Phase II Paclitaxel Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed
NCT02711553 Phase II Ramucirumab Merestinib Gemcitabine + Cisplatin A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting
NCT02411448 Phase III Erlotinib Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC Active, not recruiting
NCT02581215 Phase II Ramucirumab FOLFIRINOX Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer Recruiting
NCT02426125 Phase III Ramucirumab Docetaxel A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting
NCT02314117 Phase III Capecitabine Fluorouracil Cisplatin Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Active, not recruiting
NCT02520141 Phase II Ramucirumab Ramucirumab for Advanced Pre-treated Biliary Cancers Recruiting
NCT02435433 Phase III Ramucirumab A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) Recruiting
NCT02065765 Phase II Ramucirumab International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer No longer available